COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia.

Autor: Supangat; Department of Pharmacology, Faculty of Medicine, Universitas of Jember, Jl. Kalimantan No.37, Krajan Timur, Sumbersari, Kec. Sumbersari, 68121, Jember, Indonesia. drsupangat@unej.ac.id., Sakinah EN; Department of Pharmacology, Faculty of Medicine, Universitas of Jember, Jl. Kalimantan No.37, Krajan Timur, Sumbersari, Kec. Sumbersari, 68121, Jember, Indonesia., Nugraha MY; Faculty of Medicine, University of Jember, Jember Regency, Indonesia., Qodar TS; Faculty of Medicine, University of Jember, Jember Regency, Indonesia., Mulyono BW; Faculty of Medicine, University of Jember, Jember Regency, Indonesia., Tohari AI; Faculty of Medicine, University of Jember, Jember Regency, Indonesia.
Jazyk: angličtina
Zdroj: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2021 Oct 12; Vol. 22 (1), pp. 58. Date of Electronic Publication: 2021 Oct 12.
DOI: 10.1186/s40360-021-00528-4
Abstrakt: Introduction: Coronavirus Disease (COVID-19) caused by Novel Coronavirus named as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was declared Pandemic by The World Health Organization (WHO) and a Public Health Emergency of International Concern (PHEIC) on January 30, 2020. Many COVID-19 vaccines have been developed, including CoronaVac vaccines by Sinovac. Health care workers, along with medical clerkship students are the priority to receive the vaccine. However, the Adverse Events Following Immunization (AEFI) of the CoronaVac remains unclear. This study aims to describe and analyze the adverse events following immunization (AEFI) of COVID-19 vaccination in medical students in clerkship programs.
Method: We conducted a cross-sectional study using a questionnaire to assess AEFI after CoronaVac vaccination among medical clerkship students. A Chi-Square test with 95 % of CI was used to determine whether gender correlated with symptoms of AEFI.
Result: We identified 144 medical clerkship students. The most common AEFI of SARS-CoV-2 vaccinations was localized pain in the injection site during the first dose with 25 (45 %) reports and the booster dose with 34 (67 %) reports. Then followed by malaise, the first dose with 20 (36 %) reports and the booster dose with 21 (41 %) reports. Other symptoms like headache, fever, shivering, sleepiness, nausea, dysphagia, and cold were also reported.
Conclusions: CoronaVac SARS-COV-2 vaccine has several mild symptoms of AEFI and not correlated with gender. Nevertheless, follow-up after vaccination is needed to prevent immunologic responses that may occur in some patients.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: